Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587500 | 0.91 | HTR7 (0.52) | PPARGPPARASIGMAR1HTR7MAOB | |
| SCHEMBL9366389 | 0.90 | PPARG (0.53) | PPARGPPARASIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7393191 | 0.90 | MAOB (0.53) | PPARGPPARASIGMAR1HTR7MAOB | |
| Paliroden SCHEMBL29375649 | 0.90 | HTR7 (0.53) | PPARGPPARASIGMAR1MEN1KMT2A | |
| Paliroden SCHEMBL4587135 | 0.90 | HTR7 (0.53) | PPARGPPARASIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8742253 | 0.89 | PPARG (0.53) | PPARGPPARASIGMAR1MEN1KMT2A | |
| SCHEMBL4587555 | 0.88 | HTR7 (0.54) | PPARGPPARASIGMAR1MEN1KMT2A | |
| SCHEMBL9485644 | 0.87 | PPARG (0.53) | PPARGPPARASIGMAR1MEN1KMT2A | |
| SCHEMBL4588837 | 0.87 | PPARG (0.56) | PPARGPPARASIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7385918 | 0.87 | HTR7 (0.53) | PPARGPPARASIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148614-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | US | claimed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-20030092737-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2003-05-15 | — | — | US | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| EP-1030671-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 2000-08-30 | — | — | EP | claimed |
| WO-1999025363-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| EP-0837848-B1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI SYNTHELABO (FR) | 2002-09-11 | — | — | EP | disclosed |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6342505-B1 | inhibiting apoptosis using xaliproden hydrochloride, or other tetrahydropyridine derivatives | SANOFI-SYNTHELABO (FR) | 2002-01-29 | — | — | US | disclosed |
| EP-1030671-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 2000-08-30 | — | — | EP | disclosed |
| US-5981754-A | TREATMENT OF ANOXIA, ALZHEIMER'S DISEASE, SENILE DEMENTIA, SUBCORTICAL DEMENTIA SUCH AS HUNTINGTON'S CHOREA AND PARKINSON'S DISEASE, DEMENTIA CAUSED BY AIDS, NEUROPATHY | SANOFI (FR) | 1999-11-09 | — | — | US | disclosed |
| WO-1999025363-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | disclosed |
| EP-0837848-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997001536-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092737-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | ACHE, BCHE, PSEN1 | PPARG 1612/4885PPARA 1966/4885SIGMAR1 1064/4885 |
| US-20020091143-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 2860/4885PPARA 1980/4885SIGMAR1 1163/4885 |
| US-20050148614-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | ACHE, PSEN1, PSEN2 | PPARG 1752/4885PPARA 1956/4885SIGMAR1 750/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 3146/4885PPARA 2134/4885SIGMAR1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.